Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection

Basit Öğe Kaydı
dc.contributor.authorAydin, Dincer
dc.contributor.authorSendur, Mehmet Ali
dc.contributor.authorKefeli, Umut
dc.contributor.authorUnal, Olcun Umit
dc.contributor.authorTastekin, Didem
dc.contributor.authorAkyol, Murat
dc.contributor.authorTanrikulu, Eda
dc.date.accessioned2024-02-23T14:02:27Z
dc.date.available2024-02-23T14:02:27Z
dc.date.issued2017
dc.departmentNEÜen_US
dc.description.abstractThis is a multicenter study to assess the prognostic factors and adjuvant chemotherapy in patients with small bowel adenocarcinoma (SBA). A total of 78 patients with SBA diagnosed with completely resected SBA were involved in the study. Only status of surgical margin was determined to be an independent prognostic factor in patients with SBA who underwent curative resection. Neither disease-free survival nor overall survival was found to be significantly improved by the adjuvant chemotherapy Background: Small bowel adenocarcinoma (SBA) is a rare tumor of the gastrointestinal system with poor prognosis. Because these are rarely encountered tumors, the aim of this multicenter study was evaluation of prognostic factors and adjuvant chemotherapy in patients with curatively resected SBA. Materials and Methods: A total of 78 patients diagnosed with curatively resected SBA were involved in the retrospective study. Forty-eight patients received 1 of 3 different chemotherapy regimens, whereas 30 patients did not receive any adjuvant treatment. No adjuvant and adjuvant chemotherapy cohorts were matched (1: 1) by propensity scores based on the likelihood of receiving chemotherapy or the survival hazard from Cox modeling. Overall survival (OS) was compared with Kaplan-Meier estimates. Results: Median age of 78 patients with curatively resected SBA was 58, and 59% of these were men. According to TNM classification, 8 (10%) of the patients were at stage I, 26 (34%) were at stage II, and 44 (56%) were at stage III. Median follow-up duration was 29 months. Three-year median disease-free survival (DFS) and OS were 62.5% and 67.0%, respectively. In univariate analysis, presence of vascular invasion, perineural invasion, lymph node involvement, and presence of positive surgical margin were significant predictors of poor survival. Multivariate analysis showed that the only adverse prognostic factor independently related with OS was the presence of positive surgical margin (hazard ratio, 0.37; 95% confidence interval, 0.11-1.26; P = .01). Neither DFS nor OS was found to be significantly improved by the adjuvant chemotherapy in both matched and unmatched cohorts. Conclusions: Only status of surgical margin was determined to be an independent prognostic factor in patients with SBA who underwent curative resection.en_US
dc.identifier.doi10.1016/j.clcc.2016.08.002
dc.identifier.endpage227en_US
dc.identifier.issn1533-0028
dc.identifier.issn1938-0674
dc.identifier.issue3en_US
dc.identifier.pmid27670893en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage220en_US
dc.identifier.urihttps://doi.org/10.1016/j.clcc.2016.08.002
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11722
dc.identifier.volume16en_US
dc.identifier.wosWOS:000408269300020en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherCig Media Group, Lpen_US
dc.relation.ispartofClinical Colorectal Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdenocarcinomaen_US
dc.subjectAdjuvanten_US
dc.subjectChemotherapyen_US
dc.subjectPrognosisen_US
dc.subjectSmall Bowelen_US
dc.titleEvaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resectionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu